Understanding immune perspectives and options for the use of checkpoint immunotherapy in HCC post liver transplant

Abstract

Treatment modalities for hepatocellular carcinoma (HCC) vary from surgical techniques and interventional radiologic strategies to systemic therapy. For the latter, the use of immune checkpoint inhibitors (ICIs) has gained popularity due to successful trials showing increased survival. In patients who have undergone liver transplantation, recurrence of HCC poses a significant challenge. There is indeed considerable debate on the efficacy and safety of ICI use in liver transplant recipients due to competing immune interests in maintaining a healthy graft and combating the tumor. Recent reports and case series have highlighted a role for the type of immune therapy, timing of therapy, tissue expression of PD-1 and modulation of immunosuppression, in the understanding of the efficacy and risks of ICIs for HCC in liver transplant. In this article, we appraise the available literature on the usage of ICIs for HCC in liver transplant recipients and provide perspectives on immune concerns as well as potential recommendations to consider during the management of such complex cases.

Keywords

Hepatocellular carcinoma / liver transplant / checkpoint inhibitors

References

[1] Petrick JL,Znaor A.International trends in hepatocellular carcinoma incidence, 1978-2012.Int J Cancer2020;147:317-30 PMCID:PMC7470451

[2] Bray F,Soerjomataram I,Torre LA.Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer J Clin2018;68:394-424

[3] McGlynn KA,El-Serag HB.Epidemiology of hepatocellular carcinoma.Hepatology2021;73 Suppl 1:4-13 PMCID:PMC7577946

[4] Mittal S.Epidemiology of hepatocellular carcinoma: consider the population.J Clin Gastroenterol2013;47 Suppl:S2-6 PMCID:PMC3683119

[5] Kew MC.Hepatocellular carcinoma: epidemiology and risk factors.J Hepatocell Carcinoma2014;1:115-25 PMCID:PMC4918271

[6] Mazzaferro V,Doci R.Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis.N Engl J Med1996;334:693-9

[7] Marrero JA,Sirlin CB.Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the american association for the study of liver diseases.Hepatology2018;68:723-50

[8] Cheung TT,Yuen WK.Long-term survival analysis of pure laparoscopic versus open hepatectomy for hepatocellular carcinoma in patients with cirrhosis: a single-center experience.Ann Surg2013;257:506-11

[9] Vitale A,Giannini EG.Personalized treatment of patients with very early hepatocellular carcinoma.J Hepatol2017;66:412-23

[10] Roayaie S,Sung MW.Recurrence of hepatocellular carcinoma after liver transplant: patterns and prognosis.Liver Transpl2004;10:534-40

[11] Halazun KJ,Abdelmessih RM.Recurrence after liver transplantation for hepatocellular carcinoma: a new MORAL to the story.Ann Surg2017;265:557-64

[12] de'Angelis N,Carra MC.Managements of recurrent hepatocellular carcinoma after liver transplantation: a systematic review.World J Gastroenterol2015;21:11185-98 PMCID:PMC4607916

[13] Bodzin AS,Markovic D,Busuttil RW.Predicting mortality in patients developing recurrent hepatocellular carcinoma after liver transplantation: impact of treatment modality and recurrence characteristics.Ann Surg2017;266:118-25

[14] Guerrini GP,Tarantino G.Multimodal oncological approach in patients affected by recurrent hepatocellular carcinoma after liver transplantation.Eur Rev Med Pharmacol Sci2017;21:3421-35

[15] Couzin J.Cancer immunotherapy. Select T cells, given space, shrink tumors.Science2002;297:1973

[16] Mariotto AB,Shao Y,Brown ML.Projections of the cost of cancer care in the United States: 2010-2020.J Natl Cancer Inst2011;103:117-28 PMCID:PMC3107566

[17] Cheng A,Chen Z.Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.Lancet Oncol2009;10:25-34

[18] Llovet JM,Mazzaferro V.SHARP Investigators Study GroupSorafenib in advanced hepatocellular carcinoma.N Engl J Med2008;359:378-90

[19] Lué A,Bustamante FJ.Neutrophil-to-lymphocyte ratio predicts survival in European patients with hepatocellular carcinoma administered sorafenib.Oncotarget2017;8:103077-86 PMCID:PMC5732712

[20] Sultan A,Wondifraw Z,Bane A.Single center analysis of therapy and outcomes of hepatocellular carcinoma in Sub-Saharan Africa.Expert Rev Gastroenterol Hepatol2020;14:1007-11 PMCID:PMC7544626

[21] Wilhelm SM,Tang L.BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.Cancer Res2004;64:7099-109

[22] Bruix J,Merle P.Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.Lancet2017;389:56-66

[23] Abou-Alfa GK,Cheng AL.Cabozantinib in patients with advanced and progressing hepatocellular carcinoma.N Engl J Med2018;379:54-63 PMCID:PMC7523244

[24] Kudo M,Qin S.Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.Lancet2018;391:1163-73

[25] Zhu AX,Ryoo B.Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial.Lancet Oncol2015;16:859-70

[26] Yoong KF,Hübscher SG.Vascular adhesion protein-1 and ICAM-1 support the adhesion of tumor-infiltrating lymphocytes to tumor endothelium in human hepatocellular carcinoma.J Immunol1998;160:3978-88

[27] Hui E.Immune checkpoint inhibitors.J Cell Biol2019;218:740-1 PMCID:PMC6400575

[28] Chen L.Molecular mechanisms of T cell co-stimulation and co-inhibition.Nat Rev Immunol2013;13:227-42 PMCID:PMC3786574

[29] Gutierrez C,Reynolds D.Toxicity of immunotherapeutic agents.Crit Care Clin2021;37:605-24

[30] El-khoueiry AB,Yau T.Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.Lancet2017;389:2492-502 PMCID:PMC7539326

[31] Finn RS,Merle P.KEYNOTE-240 investigatorsPembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial.J Clin Oncol2020;38:193-202

[32] Yau T,Finn R.CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC).Ann Oncol2019;30:v874-5

[33] Finn RS,Ikeda M.IMbrave150 InvestigatorsAtezolizumab plus bevacizumab in unresectable hepatocellular carcinoma.N Engl J Med2020;382:1894-905

[34] Ren Z,Xu J.LBA2 Sintilimab plus bevacizumab biosimilar vs sorafenib as first-line treatment for advanced hepatocellular carcinoma (ORIENT-32)2.Ann Oncol2020;31:S1287

[35] Sangro B,Hervás-Stubbs S.Advances in immunotherapy for hepatocellular carcinoma.Nat Rev Gastroenterol Hepatol2021;18:525-43 PMCID:PMC8042636

[36] Huang H,Zhou T,Xia Q.Innate immune cells in immune tolerance after liver transplantation.Front Immunol2018;9:2401 PMCID:PMC6237933

[37] Thomson AW.Antigen-presenting cell function in the tolerogenic liver environment.Nat Rev Immunol2010;10:753-66

[38] de la Garza RG,Merino J.Trial of complete weaning from immunosuppression for liver transplant recipients: factors predictive of tolerance.Liver Transpl2013;19:937-44

[39] Feng S,Mazariegos GV.Efficacy and safety of immunosuppression withdrawal in pediatric liver transplant recipients: moving toward personalized management.Hepatology2021;73:1985-2004

[40] Starzl TE,Vonkaulla KN,Brittain RS.Homotransplantation of the liver in humans.Surg Gynecol Obstet1963;117:659-76 PMCID:PMC2634660

[41] Starzl TE,Waddell WR.The reversal of rejection in human renal homografts with subsequent development of homograft tolerance.Surg Gynecol Obstet1963;117:385-95 PMCID:PMC2581919

[42] Eason JD,Blazek J,Mason AL.Steroid-free liver transplantation using rabbit antithymocyte globulin induction: results of a prospective randomized trial.Liver Transpl2001;7:693-7

[43] Anugwom CM,Hwang C,Lee WM.Comparison of clinical outcomes of induction regimens in patients undergoing liver transplantation for acute liver failure.Liver Transpl2021;27:27-33

[44] Cangemi M,Faè DA,Dolcetti R.Dissecting the multiplicity of immune effects of immunosuppressive drugs to better predict the risk of de novo malignancies in solid organ transplant patients.Front Oncol2019;9:160 PMCID:PMC6445870

[45] Wai LE,Takeda S,Krams SM.Rapamycin, but not cyclosporine or FK506, alters natural killer cell function.Transplantation2008;85:145-9 PMCID:PMC4084728

[46] Colic M,Pavlovic B,Stefanoska I.Mycophenolate mofetil inhibits differentiation, maturation and allostimulatory function of human monocyte-derived dendritic cells.Clin Exp Immunol2003;134:63-9 PMCID:PMC1808848

[47] Bhat M,Dierkhising R.Gender, race and disease etiology predict de novo malignancy risk after liver transplantation: insights for future individualized cancer screening guidance.Transplantation2019;103:91-100

[48] Mathur A,Leone JP.Obesity portends increased morbidity and earlier recurrence following liver transplantation for hepatocellular carcinoma.HPB (Oxford)2013;15:504-10 PMCID:PMC3692019

[49] Liang W,Ling X.Sirolimus-based immunosuppression in liver transplantation for hepatocellular carcinoma: a meta-analysis.Liver Transpl2012;18:62-9

[50] Jiang Y,Fenton SS,Lilly L.Liver transplantation and subsequent risk of cancer: findings from a Canadian cohort study.Liver Transpl2008;14:1588-97

[51] Haagsma EB,Schaapveld M.Increased cancer risk after liver transplantation: a population-based study.J Hepatol2001;34:84-91

[52] Sapisochin G,Astete S.Benefit of treating hepatocellular carcinoma recurrence after liver transplantation and analysis of prognostic factors for survival in a large Euro-American series.Ann Surg Oncol2015;22:2286-94

[53] Schlitt HJ,Weimann A.Recurrence patterns of hepatocellular and fibrolamellar carcinoma after liver transplantation.J Clin Oncol1999;17:324-31

[54] Gomez-Martin C,Castroagudin JF.Efficacy and safety of sorafenib in combination with mammalian target of rapamycin inhibitors for recurrent hepatocellular carcinoma after liver transplantation.Liver Transpl2012;18:45-52

[55] Haanen JBAG,Robert C.ESMO Guidelines CommitteeManagement of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Ann Oncol2017;28:iv119-42

[56] Biondani P,Samuel D.Safety of an anti-PD-1 immune checkpoint inhibitor in a liver transplant recipient.Ann Oncol2018;29:286-7

[57] De Toni EN, Gerbes AL. Tapering of immunosuppression and sustained treatment with nivolumab in a liver transplant recipient.Gastroenterology2017;152:1631-3

[58] Anugwom C.Nivolumab-induced autoimmune-like cholestatic hepatitis in a liver transplant recipient.ACG Case Rep J2020;7:e00416 PMCID:PMC7363460

[59] Friend BD,McDiarmid SV.Fatal orthotopic liver transplant organ rejection induced by a checkpoint inhibitor in two patients with refractory, metastatic hepatocellular carcinoma.Pediatr Blood Cancer2017;64:e26682

[60] Owoyemi I,Costello CM.Clinical outcomes of solid organ transplant recipients with metastatic cancers who are treated with immune checkpoint inhibitors: a single-center analysis.Cancer2020;126:4780-7 PMCID:PMC8772343

[61] Wang TF,Carrier M.Thrombotic complications associated with immune checkpoint inhibitors.Cancers (Basel)2021;13:4606 PMCID:PMC8469452

[62] Moik F,Wiedemann S.Incidence, risk factors, and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy.Blood2021;137:1669-78 PMCID:PMC8016631

[63] López-Cortés A,Silva L.Identification of key proteins in the signaling crossroads between wound healing and cancer hallmark phenotypes.Sci Rep2021;11:17245 PMCID:PMC8390472

[64] Elias AW,Stauffer JA.The feasibility and safety of surgery in patients receiving immune checkpoint inhibitors: a retrospective study.Front Oncol2017;7:121 PMCID:PMC5466999

[65] Sun J,Chung JL.Perioperative outcomes of melanoma patients undergoing surgery after receiving immunotherapy or targeted therapy.World J Surg2020;44:1283-93

[66] Abdel-Wahab N,Abudayyeh A.Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature.J Immunother Cancer2019;7:106 PMCID:PMC6469201

[67] Gassmann D,Mertens JC.Liver allograft failure after nivolumab treatment-a case report with systematic literature research.Transplant Direct2018;4:e376 PMCID:PMC6092180

[68] Kumar V,Rennke HG.The safety and efficacy of checkpoint inhibitors in transplant recipients: a case series and systematic review of literature.Oncologist2020;25:505-14 PMCID:PMC7288631

[69] Blazar BR,Panoskaltsis-Mortari A.Blockade of programmed death-1 engagement accelerates graft-versus-host disease lethality by an IFN-gamma-dependent mechanism.J Immunol2003;171:1272-7

[70] Munker S.Use of checkpoint inhibitors in liver transplant recipients.United European Gastroenterol J2018;6:970-3 PMCID:PMC6137599

[71] Chen GH,Huang F.Pretransplant use of toripalimab for hepatocellular carcinoma resulting in fatal acute hepatic necrosis in the immediate postoperative period.Transpl Immunol2021;66:101386

[72] Tabrizian P,Schwartz ME.PD-1 inhibitor as bridge therapy to liver transplantation?.Am J Transplant2021;21:1979-80

[73] Qiao ZY,Lv ZC.Neoadjuvant programmed cell death 1 (PD-1) inhibitor treatment in patients with hepatocellular carcinoma before liver transplant: a cohort study and literature review.Front Immunol2021;12:653437 PMCID:PMC8326904

[74] DeLeon TT,Aqel BA.Pilot evaluation of PD-1 inhibition in metastatic cancer patients with a history of liver transplantation: the Mayo Clinic experience.J Gastrointest Oncol2018;9:1054-62 PMCID:PMC6286929

[75] Dueland S,Boberg KM.Acute liver graft rejection after ipilimumab therapy.Ann Oncol2017;28:2619-20

[76] Herbaux C,Brice P.Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphoma.Blood2017;129:2471-8

[77] Lechler RI,Thomson AW.Organ transplantation--how much of the promise has been realized?.Nat Med2005;11:605-13

[78] Lei H,Volk HD,Wu R.Mechanisms of immune tolerance in liver transplantation-crosstalk between alloreactive T cells and liver cells with therapeutic prospects.Front Immunol2019;10:2667 PMCID:PMC6877506

[79] Du X,Guo W,Chen ZK.Progress in liver transplant tolerance and tolerance-inducing cellular therapies.Front Immunol2020;11:1326 PMCID:PMC7326808

[80] Varkaris A,Nugent FW.Preserved liver transplant after PD-1 pathway inhibitor for hepatocellular carcinoma.Am J Gastroenterol2017;112:1895-6

[81] Hua H,Zhang H,Luo T.Targeting mTOR for cancer therapy.J Hematol Oncol2019;12:71 PMCID:PMC6612215

[82] Zheng Y.mTOR inhibitors at a glance.Mol Cell Pharmacol2015;7:15-20 PMCID:PMC4849280

[83] Tsung I,Fontana RJ.A pilot study of checkpoint inhibitors in solid organ transplant recipients with metastatic cutaneous squamous cell carcinoma.Oncologist2021;26:133-8 PMCID:PMC7873324

[84] Rao RD,Sarkaria JN.Mammalian target of rapamycin (mTOR) inhibitors as anti-cancer agents.Curr Cancer Drug Targets2004;4:621-35

[85] Smedman TM,Guren TK.Graft rejection after immune checkpoint inhibitor therapy in solid organ transplant recipients.Acta Oncol2018;57:1414-8

[86] Nguyen LS,Lebrun-Vignes B.Transplant rejections associated with immune checkpoint inhibitors: a pharmacovigilance study and systematic literature review.Eur J Cancer2021;148:36-47

[87] Kittai AS,Cetnar J.Immune checkpoint inhibitors in organ transplant patients.J Immunother2017;40:277-81

[88] Ros J,Martin-Liberal J.Immunotherapy in organ-transplanted cancer patients: efficacy and risk of organ rejection.Ann Oncol2019;30:1173-7

[89] Tanaka K,Yuan X.PDL1 is required for peripheral transplantation tolerance and protection from chronic allograft rejection.J Immunol2007;179:5204-10 PMCID:PMC2291549

[90] Au KP.Immunotherapy after liver transplantation: where are we now?.World J Gastrointest Surg2021;13:1267-78 PMCID:PMC8554723

[91] Gao H,Tu H.Development of T cells redirected to glypican-3 for the treatment of hepatocellular carcinoma.Clin Cancer Res2014;20:6418-28

[92] Jiang Z,Chen S.Anti-GPC3-CAR T cells suppress the growth of tumor cells in patient-derived xenografts of hepatocellular carcinoma.Front Immunol2016;7:690 PMCID:PMC5225101

[93] Tan AT,Lee Krishnamoorthy T.Use of expression profiles of HBV-DNA integrated into genomes of hepatocellular carcinoma cells to select T cells for immunotherapy.Gastroenterology2019;156:1862-76.e9

[94] Hafezi M,Bertoletti A.Personalized armored TCR-redirected T cell therapy for liver/organ transplant with recurrent cancer.Cells2021;10:1861 PMCID:PMC8393584

[95] Qasim W,Gehring AJ.Immunotherapy of HCC metastases with autologous T cell receptor redirected T cells, targeting HBsAg in a liver transplant patient.J Hepatol2015;62:486-91

[96] Tagliamonte M,Mauriello A,Buonaguro FM.Potentiating cancer vaccine efficacy in liver cancer.Oncoimmunology2018;7:e1488564 PMCID:PMC6169594

[97] Mizukoshi E,Tsuji H,Kaneko S.Identification of alpha-fetoprotein-derived peptides recognized by cytotoxic T lymphocytes in HLA-A24+ patients with hepatocellular carcinoma.Int J Cancer2006;118:1194-204

[98] Samson A,Scott K.Oncolytic reovirus as a combined antiviral and anti-tumour agent for the treatment of liver cancer.Gut2018;67:562-73 PMCID:PMC5868283